<DOC>
	<DOCNO>NCT02610543</DOCNO>
	<brief_summary>This Phase 2 , multicenter , double-blind , placebo-controlled , 12-week proof-of-concept study ass efficacy , safety , tolerability UCB5857 subject primary Sjogren 's Syndrome ( pSS ) . The primary objective study evaluate efficacy overall disease activity safety UCB5857 add current treatment relative placebo subject pSS .</brief_summary>
	<brief_title>UCB Proof Concept Study Patients With Primary Sjogren 's Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Sjogren 's Syndrome</mesh_term>
	<criteria>Subject must 18 year 75 year age Women childbearing potential must agree use highly effective method birth control study period 3 month final dose study drug . Women agree use birth control must nonchildbearing potential define ; permanently sterile , congenitally sterile postmenopausal least 2 year prior Screening ( Visit 1 ) . Women childbearing potential require serum pregnancy test take Screening ( Visit 1 ) , confirm negative urine test prior first dose study drug Week 1 ( Visit 2 ) Male subject partner childbearing potential must willing use condom sexually active study 3 month last dose study drug In addition female partner childbearing potential male subject must willing use highly effective method contraception duration study 3 month last dose study drug Subject must meet 2002 AECG ( AmericanEuropean Consensus Group ) criteria Primary Sjogren 's Syndrome Subject must serum test positive antiSSA/Ro ( Ro52 Ro60 ) and/or anti SSB/La autoantibody Subject diagnosis autoimmune disease , ie , secondary Sjogren 's syndrome ( eg , rheumatoid arthritis , systemic lupus erythematosus Subject diagnosis sicca syndrome ( eg , history head neck radiation treatment , sarcoidosis chronic graftversushost disease ) Subject significant fibromyalgia syndrome define American College Rheumatology 2010 classification criterion . Subject significant depression define 5th edition Diagnostic Statistical Manual Mental Disorders . Subject oral candidiasis Subject female breastfeeding , pregnant , plan become pregnant start breastfeeding study within 3 month final dose investigational medicinal product ( IMP ) Subject evidence immunosuppressive state , include human immunodeficiency virus ( HIV ) infection , hypogammaglobulinemia , Tcell deficiencies , human Tcell leukemia virus type 1 ( HTLV1 ) Positive test HIV1/2 Screening ( Visit 1 ) Subject history chronic infection , include limited concurrent acute chronic viral hepatitis B ( HBV ) hepatitis C ( HCV ) tuberculosis ( TB ) Positive test HBV Screening ( Visit 1 ) Positive test HCV Screening ( Visit 1 ) Positive test TB Screening ( Visit 1 ) A subject history recent serious lifethreatening infection current sign symptom may indicate significant infection Screening ( Visit 1 ) randomization , per Investigator 's clinical judgment also exclude Subject must complete prior antiinfective therapy prior first dose study drug exception antiinfectives take specifically treatment acne , rosacea , onychomycosis , vaginal yeast infection ; prophylaxis urinary tract infection ; prophylaxis presurgical preprocedural reason ( include dental procedure ) Note : minocycline may use purpose Subject particularly high risk significant infection due lifestyle and/or occupation Subject receive intranasal influenza vaccine within 8 week prior Screening ( Visit 1 ) Subject significant hematologic abnormality hemoglobin &lt; 8.0 g/dL , white blood cell ( WBC ) &lt; 2000 /mm^3 , absolute neutrophil count &lt; 1000 /mm^3 , platelet &lt; 30,000 /mm^3 Screening ( Visit 1 ) Subject history cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Primary Sjogren 's Syndrome</keyword>
</DOC>